Immatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics N.V. (NASDAQ: IMTX) reported Q2 2026 results and a SUPRAME Phase 3 update for anzu-cel (IMA203) in advanced melanoma. PFS events are occurring more slowly than modeled, so the company will use a single streamlined final PFS analysis and add ~90 patients to strengthen OS. SUPRAME final PFS topline is expected H1 2027, with BLA submission in 2027. Cash: $448.2M as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The key new trading-relevant item is the SUPRAME statistical plan change driven by observed event rates and FDA feedback, alongside a stated schedule for final PFS topline (H1 2027) and BLA submission (2027).
Market read
Traders can update probability-of-success and regulatory-readiness expectations based on the revised SUPRAME analysis approach and the reaffirmed 2027 regulatory milestones.
What to watch
The article does not quantify the revised event threshold or how FDA feedback specifically altered assumptions; investors may discount the change until protocol amendment details are filed.
Background
Immatics is advancing PRAME-targeted programs, with anzu-cel (IMA203) in the Phase 3 SUPRAME trial for advanced melanoma and earlier Phase 1/1b data presented at ASCO 2026.
Ticker impact
Immatics says SUPRAME PFS events are occurring more slowly than modeled, prompting a streamlined final PFS analysis and added OS power.
Near-term sentiment likely positive on reduced uncertainty around PFS readout, but investors may still focus on the unchanged timing to H1 2027 topline.
The article discloses a concrete FDA-feedback-driven change to trial analysis (event count, streamlined PFS, OS power increase) plus a stated topline and BLA timeline, which can affect perceived probability of success and regulatory readiness.
Market effects
Adds incremental signal for PRAME-targeted cell therapy development timelines and FDA interaction norms for oncology trial statistical designs.
Limited direct regional impact; trial enrollment spans North America and Europe.
Moderate relevance for global oncology biotech sentiment around PRAME franchise execution and regulatory planning.
Counterpoint
Slower-than-modeled PFS event accrual could also reflect less favorable disease kinetics than expected, even if the company frames it as enabling a streamlined analysis.
Key entities
- companyImmatics N.V.
NASDAQ-listed precision targeting PRAME cell therapy and bispecific developer.
- clinical_trialSUPRAME (Phase 3)
Randomized controlled Phase 3 trial of anzu-cel (IMA203) in previously treated advanced melanoma, with PFS as primary endpoint.
- product_candidateanzu-cel (IMA203, anzutresgene autoleucel)
Lead PRAME cell therapy expected to be first PRAME therapy to enter the market in advanced melanoma.
- regulatorFDA
Provided feedback leading to protocol amendments for SUPRAME analysis strategy.
